Adage Capital Partners’s Aspire Biopharma Warrant ASBPW Stock Holding History

Adage Capital Partners’s Portfolio ASBPW Stock Details ASBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21K	Hold	1,050,000	–	–	﹤0.01%	995
2026 Q1	$17.4K	Hold	1,050,000	–	–	﹤0.01%	952
2025 Q4	$17.3K	Hold	1,050,000	–	–	﹤0.01%	901
2025 Q3	$31.4K	Hold	1,050,000	–	–	﹤0.01%	867
2025 Q2	$46.9K	Hold	1,050,000	–	–	﹤0.01%	838
2025 Q1	$71.1K	Hold	1,050,000	–	–	﹤0.01%	826
2024 Q4	$1.05K	Hold	1,050,000	–	–	﹤0.01%	866
2024 Q3	$1.05K	Hold	1,050,000	–	–	﹤0.01%	849
2024 Q2	$1.05K	Hold	1,050,000	–	–	﹤0.01%	842
2024 Q1	$31.6K	Hold	1,050,000	–	–	﹤0.01%	849
2023 Q4	$63K	Hold	1,050,000	–	–	﹤0.01%	803
2023 Q3	$53.2K	Hold	1,050,000	–	–	﹤0.01%	827
2023 Q2	$52.6K	Hold	1,050,000	–	–	﹤0.01%	826
2023 Q1	$43.9K	Hold	1,050,000	–	–	﹤0.01%	887
2022 Q4	$83.9K	Hold	1,050,000	–	–	﹤0.01%	891
2022 Q3	$116K	Hold	1,050,000	–	–	﹤0.01%	947
2022 Q2	$179K	Buy	+1,050,000	New	+$228K	﹤0.01%	965

Other funds holding ASBPW

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Adage Capital Partners's ASBPW Position: Q2 2026 in Review

Adage Capital Partners held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2026 at 1,050,000 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #995.

Adage Capital Partners first reported a position in ASBPW in Q2 2022 and has held it in 17 quarters since. The position peaked at $179K in Q2 2022. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

Adage Capital Partners held 1,050,000 shares of Aspire Biopharma Warrant worth $21K as of Q2 2026.
Adage Capital Partners left its Aspire Biopharma Warrant share count unchanged in Q2 2026.
Aspire Biopharma Warrant made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #995 holding.
Adage Capital Partners first reported a position in Aspire Biopharma Warrant in Q2 2022 and has held it in 17 quarters since.
Adage Capital Partners's Aspire Biopharma Warrant position peaked at $179K in Q2 2022.
27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.